2MePI
| Clinical data | |
|---|---|
| Drug class | Serotonin receptor modulator; Serotonin 5-HT2A receptor weak partial agonist or functional antagonist |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C12H14N2 |
| Molar mass | 186.258 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
2MePI, also known as 2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole, is a serotonin receptor modulator of the pyridoindole (γ-carboline) family. It is the pyridoindole homologue of the ibogalog (azepinoindole) ibogaminalog (DM-506).
The drug acts as a weak partial agonist or functional competitive antagonist of the serotonin 5-HT2A receptor, with an affinity (Ki) of 95 nM, an EC50 (Emax) of 533 nM (32%), an apparent IC50 of 3,100 to 18,000 nM, and a KB of 89 to 228 nM. Compared to ibogaminalog, 2MePi had 5-fold lower affinity, 59-fold lower activational potency, and less than half the activational efficacy at the serotonin 5-HT2A receptor. Results were analogous for 8MeO-2MePI against ibogainalog (8MeO-2MePI's ibogalog homologue). These findings indicate that ibogalogs are the more optimal structural scaffold for serotonin 5-HT2A receptor agonism.
2MePI was first described in the scientific literature by Matthias Liechti and colleagues in 2026.
- 2MePI
- 8MeO-2MePI
- Drugs not assigned an ATC code